Medical spas are regulated by a patchwork of state rules and regulations usually governed by a medical board. In addition to standards and protocols regarding delegation/supervision of non-physicians such as physician-assistants, nurse practitioners... Read More
Frier Levitt attorney Dr. Lawrence F. Kobak, DPM, Esq., published an article, “Closure of a Podiatric Practice” in the November/December 2023 issue of Podiatry Management. The article discusses common concerns podiatrists face when closing a... Read More
On November 1, 2023, a bipartisan group of senators announced that they had reintroduced legislation to expand and eliminate barriers to treat opioid use disorder (OUD) through telehealth. Specifically, the Telehealth Response for E-prescribing... Read More
This summer, the Office for Civil Rights (OCR) and the Federal Trade Commission (FTC) issued and published warnings to over 120 hospitals and telehealth providers regarding third-party online tracking technologies that may be integrated into their... Read More
On October 3rd, 2023, the U.S. Food and Drug Administration (FDA) published a proposed rule to clarify and confirm that in vitro diagnostic products (IVDs), including certain laboratory developed tests (LDTs), are considered devices under the... Read More
In 2022, following the lead of many states, including New Jersey with the Out-of-Network Consumer Protection, Transparency, Cost Containment, and Accountability Act, the federal No Surprises Act (“NSA”) was enacted to address billing disputes... Read More
In November 2023, a South Carolina federal district court in Genesis Health Care, Inc., v. Becerra, et al. addressed the long-standing issue of who qualifies as a “patient” of a covered entity pursuant to the federal 340B program, and paved the... Read More
Medical and Pharmacy Providers must be aware of the Government’s expressed intention to increase healthcare fraud investigations. To combat the increasing prevalence of call centers and telemarketing in the healthcare space and the potential for... Read More
On November 8th, 2023, the FDA approved Eli Lilly and Co.’s new weight loss drug, Zepbound. This approval comes amid a growing shortage of semaglutide-based drugs, such as Ozempic and Wegovy, which are commonly prescribed “off-label” for... Read More
Frier Levitt partner Guillermo Beades published an article, “What to do During a Medical Board Investigation” in Physicians Practice, where he discusses the intricacies of a medical board investigation. Professional licensing boards serve an... Read More
